Press Release

Date: September 22, 2026 Listing Department Department of Corporate Service National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, G Block, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai - 400 051. Dalal Street, Mumbai - 400 001. Symbol: SYRMA Scrip Code: 543573 Subject: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “Listing Regulations”) – update on inauguration of facility by Syrma Johri MedTech Limited, a subsidiary of Syrma SGS Technology Limited (“Syrma SGS/Company”) -Press Release. Dear Sir/ Madam, Pursuant to Regulation 30 of the Listing Regulations, please find enclosed a Press Release on inauguration of a new Medical Plastics and Precision Molding Facility in Jodhpur by Syrma Johri MedTech Limited, a Subsidiary of the Company titled “Syrma Johari MedTech, a Syrma SGS Technology company inaugurates new Medical Plastics and Precision Molding Facility in Jodhpur.” Please take the above intimation on your record. Thanking you For Syrma SGS Technology Limited Bhabagrahi Pradhan Company Secretary Place: Gurgaon ENCL: as above. Syrma Johari MedTech, A Syrma SGS Technology company inaugurates new Medical Plastics and Precision Molding Facility in Jodhpur New facility strengthens the company’s integrated MedTech manufacturing capabilities and expands capacity to support global medical-device programmes Jodhpur| 22nd September 2026: Syrma Johari MedTech Limited, a Syrma SGS Technology company (BSE: SYRMA; 543573 | NSE: INE0DYJ01015), today inaugurated its new Medical Plastics and Precision Molding Facility in Jodhpur, Rajasthan, marking an important milestone in the company’s continued expansion of its MedTech manufacturing capabilities. With a plant area of 120,000+ sq. ft., the Jodhpur facility brings together capabilities in medical plastics and precision molding, including injection molding, extrusion, blow molding and tooling. The facility is designed to support the manufacture of precision medical components, including multi-cavity and tight-tolerance molded components, medical and diagnostic tubing, customized tubing profiles and other specialized applications. The Jodhpur facility further strengthens the broader manufacturing ecosystem of the Syrma SGS Group, with 17 global production sites and four design and innovation centres. Across the Group, these capabilities support customers through various stages of the product lifecycle, from design and engineering to manufacturing, tooling and assembly. Commenting on the inauguration, Sandeep Tandon, Executive Chairman, Syrma SGS Technology Limited, said: “The inauguration of the Jodhpur facility marks an important milestone in the evolution of our MedTech capabilities and reflects our long-term commitment to building specialised, high-value manufacturing capabilities in India in this industry. As the global MedTech industry continues to evolve, we see significant opportunity to contribute through investments in precision manufacturing, technology and scale. This facility strengthens the capabilities of the Syrma SGS Group and reinforces our commitment to supporting global MedTech customers while contributing to the development of a stronger and more competitive manufacturing ecosystem in India.” The new facility further strengthens Syrma Johari MedTech’s position as a design-led global MedTech CDMO, with capabilities spanning design and engineering, precision plastics, tooling, manufacturing, cleanroom operations and assembly. The company supports MedTech programmes across areas including diagnostics, medical aesthetics, patient monitoring, surgical and interventional care, critical care, rehabilitation and physical therapy. About Syrma Johari MedTech Limited Syrma Johari MedTech Limited, a Syrma SGS company, is a design-led global MedTech CDMO supporting the medical-device lifecycle from design and engineering to manufacturing, regulatory compliance and commercialisation. With a heritage dating back to 1979, the company serves MedTech programmes across diagnostics, medical aesthetics, patient monitoring, surgical and interventional care, critical care, rehabilitation and physical therapy. Its capabilities span design and engineering, precision plastics, tooling, cleanroom manufacturing, assembly, quality assurance and regulatory support. About Syrma SGS Technology Limited: Syrma SGS Technology (BSE: SYRMA; 543573 | NSE: INE0DYJ01015) is a leading Indian Electronic Systems Design and Manufacturing company. With over 45 years of expertise, Syrma SGS has been the preferred partner for customers seeking innovative and efficient solutions. The Company serves more than 270 customers across 20+ countries. It has a pan-India manufacturing footprint with 17 facilities across India, along with R&D centres in Chennai, Pune, Gurgaon, and Stuttgart, Germany. The Company offers a comprehensive range of services, including Product Design, Assembly (PCBA & Box Build), Quick Prototyping, and Tester Development Services, positioning us as a catalyst for growth in the industry. In addition to EMS, Syrma SGS also provides OEM solutions for RFID tags & inlays, high-frequency magnetic components, and electro-mechanicals. The Company’s commitment to excellence is evident in the hundreds of millions of units delivered globally in the past decade, and the multi-decadal relationships with several global customers. Website: https://syrmasgs.com/ For more information, contact: Branding Edge Syrma SGS Media Relations - Shreeya Namjoshi Nikhil Gupta, Head Investor Relations shreeya@brandingedgestrategies.com nikhil.gupta@syrmasgs.com M: +91 77158 36283 T: +91 11 4700 2122 Safe Harbour Statement: This document contains certain forward-looking statements within the meaning of applicable securities laws and regulations. These statements are based on management’s current expectations, assumptions, estimates, and projections about the business, industry, and markets in which the Company operates. Such statements include, but are not limited to, statements relating to the Company’s financial position, business strategy, plans, future operations, and objectives of management. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, that may cause actual results, performance, or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: general economic and business conditions in India and overseas, changes in government regulations, tax laws, and other statutes, as well as other factors affecting the Company’s business and operations. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, unless required by law. Investors are advised not to place undue reliance on these forward-looking statements, which speak only as of their respective dates.